biosimilars | Pharmaphorum

biosimilars

News

Card image cap

AbbVie's Humira finally faces biosimilar challenge in US

AbbVie's cash-cow immunology product Humira has its first biosimilar competition in the US market with the launch of Amgen's copycat product Amjevita, several years after

Views & Analysis

Card image cap

New technology is now the beating heart of patient care

Patient care and healthcare provision have always appeared among society’s top priorities, but keeping people well came into sharp focus during the pandemic.

R&D

Card image cap

Sandoz’s Pierre Bourdage on biosimilars: the pharmaphorum po...

In the latest episode of the podcast Dominic Tyer speaks with Pierre Bourdage, who’s global head of biopharmaceuticals at Sandoz about the big issues in biosimilars.

News

Card image cap

Alvotech files lawsuit challenging AbbVie's Humira patent th...

Biosimilars firm Alvotech has filed a lawsuit that challenges AbbVie’s legal defences surrounding the inflammatory disease drug Humira in the US.

Views & Analysis

Card image cap

2021 market access prospects for Spain

2021 will be the year when big market access changes – including the far wider use of health economic evaluation – are implemented in Spain.

Views & Analysis

Card image cap

Osteoporosis treatment options - down to the bare bones

It is World Osteoporosis Day this month, and Ben Hargreaves takes a look at what treatment options look like for patients living with the disease.